Postoperative Fasting Blood Glucose Predicts Prognosis in Stage I-III Colorectal Cancer Patients Undergoing Resection

Abstract

Purpose. The relationship between high blood glucose and colorectal cancer (CRC) has been studied, but the role of postoperative fasting blood glucose (FBG) in patients with a prior normal FBG has never been addressed. Methods. A total of 120 CRC patients staged I-III were enrolled, and the prognostic value of postoperative FBG for disease-free survival (DFS) was determined by Kaplan-Meier analysis. Univariate and multivariate analyses were conducted to test other clinicopathological parameters, including preoperative hemoglobin (HGB) and the neutrophil-lymphocyte ratio (NLR). Results. By a cut-off point of 5.11 mmol/L, 51 and 69 patients were divided into low postoperative FBG (<5.11 mmol/L) and high postoperative FBG (≥5.11 mmol/L) groups, respectively. A high postoperative FBG was more common in older age (P=0.01), left-located tumor (P=0.02), smaller tumor diameter (P=0.01), node negative involvement (P=0.01), lesser positive lymph nodes (P=0.02), and high preoperative HGB (P=0.01). Further, high postoperative FBG patients displayed a significantly better DFS than low postoperative FBG patients (48.80±22.12 months vs. 40.06±24.36 months, P=0.04), but it was less likely to be an independent prognostic factor. Conclusions. Postoperative FBG plays a temporal prognostic role for patients with stage I-III CRC with a prior normal FBG, but it is not an independent prognostic factor.

Concurrent Comparison of the Prognostic Values of Tumor Budding, Tumor Stroma Ratio, Tumor Infiltrating Pattern and Lymphocyte-to-Monocyte Ratio in Colorectal Cancer Patients

“…The exclusion criteria were as follows: 1. age <18 years old; 2. complications requiring glucocorticoids or other immunosuppressors; 3. any neoadjuvant therapies; 4. absence of laboratory tests within a week before surgery or key information loss in postoperative pathological reports; 5. multiple or recurrent malignancies, in situ lesions; and 6. lost to follow-up or follow-up period was less than 36 m. Clinicopathological parameters were collected as previously described. 31 The study was approved by the ethics committee of the Hainan Hospital of the PLA General Hospital (approved ID: 301HLFYLS15), and written informed consent was obtained from the patients or his/her authorized relatives.…”

The Value of Inflammatory Cell Count and Its Ratio in the Diagnosis of Prostate Cancer

“…Many studies have shown that in ammation is related to the occurrence, development and metastasis of malignant tumors [7][8][9][10][11]. Because the leukocyte count and various types of white blood cells are indicators of systemic in ammation and immune response, these values may be good candidate biomarkers for predicting aggressive tumors.…”

Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3+ T regulatory cells in colorectal cancer

“…From December 2012 to January 2018, CRC patients with radical recession of primary lesions in Hainan Hospital of Chinese PLA General Hospital were enrolled, and patients were excluded if they met any one of the following criteria: 1. neoadjuvant therapies; 2. missing laboratory tests within a week before surgery or key information in postoperative pathological reports; 3. multiple or recurrent malignancies or in situ lesions; or 4. loss to follow-up or less than 36 months. Other clinicopathological parameters, including body mass index (BMI) and tumor size (TS), were collected as previously reported [ 29 – 31 ]. The study was conducted in accordance with the principles stated in the Declaration of Helsinki and was approved by the ethics committee of Hainan Hospital of Chinese PLA General Hospital (ID: 301HLFYLS15), written informed consent was obtained from the patients or their authorized relatives.…”